Recent Updates
Recently added Catalysts

Vicks Active SymptoMax Plus for

Phase 1

Bioequivalence | Small molecule | Other |Johnson & Johnson|Last Updated: Jul 6, 2018

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment72

FDA Designations

No designations recorded

Clinical trial landscape

Vicks Active SymptoMax Plus for · 1 trial · 2 indications

Phase 1 1
NCT03213353A Bioequivalence Study Between Two Brands of Medications to Treat Cough & Cold SymptomsBioequivalence
COMPLETED72 Analytics
PHASE1COMPLETED
A Bioequivalence Study Between Two Brands of Medications to Treat Cough & Cold Symptoms
BioequivalenceUnlock trial analytics

Study Endpoints

Primary Endpoints

Peak Plasma Concentration (Cmax) of paracetamol, guaifenesin and phenylephrine (total)
At baseline and during 12 hours after product administration

The maximum observed plasma concentration (Cmax)

The area under the plasma concentration-vs.-time curves from start of drug administration until the time of the last measurable concentration (AUCt) for paracetamol, guaifenesin and phenylephrine (total)
At baseline and during 12 hours after product administration

AUCt is defined as area under the plasma concentration versus time curves from start of drug administration until the last measureable concentration.

The area under the concentration-vs.-time curve extrapolated to infinity (AUC∞) for paracetamol, guaifenesin and phenylephrine (total)
At baseline and during 12 hours after product administration

AUC∞ is defined as area under the plasma concentration versus time curves from start of drug administration until the plasma concentration is negligible (infinity).

The extrapolated part of AUC∞, AUCExtrap of paracetamol, guaifenesin and phenylephrine (total)
From 12 hours after start of drug administration until up to 96 hours

AUCextrap is defined as area under the plasma concentration versus time curves from 12 hours until infinity

The time at which the maximum plasma concentration is observed (tmax) for paracetamol, guaifenesin and phenylephrine (total)
At baseline and during 12 hours after product administration

Tmax is defined as the time point at which the maximum plasma concentration (Cmax) occurs

The half-life (t1/2) for paracetamol, guaifenesin and phenylephrine (total) in plasma
At baseline and during 12 hours after product administration

The half-life i defined as the time taken for the plasma concentration to fall to half its original value

The terminal elimination rate constant (λz) for paracetamol, guaifenesin and phenylephrine (total) in plasma
At baseline and during 12 hours after product administration

The terminal elimination rate constant is the rate at which the drug is removed from the body system

The mean residence time (MRT) for paracetamol, guaifenesin and phenylephrine (total)
At baseline and during 12 hours after product administration

Mean residence time (MRT) is the average amount of time that a single molecule of drug stays in the body

Secondary Endpoints

Peak Plasma Concentration (Cmax) of unconjugated phenylephrine
At baseline and during 12 hours after product administration
The area under the plasma concentration-vs.-time curves from start of drug administration until the time of the last measurable concentration (AUCt) for unconjugated phenylephrine
At baseline and during 12 hours after product administration
The area under the concentration-vs.-time curve extrapolated to infinity (AUC∞) for unconjugated phenylephrine
At baseline and during 12 hours after product administration
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelCROSSOVER
PurposeOTHER

Treatment Arms

ArmTypeDescription
Treatment sequence ABEXPERIMENTALTreatment A (experimental): Two tablets of Combination tablet with paracetamol, guaifenesin and phenylephrine hydrochloride each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride Treatment B (active comparator): One sachet Vicks Active SymptoMax Plus, powder for oral solution, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride
Treatment sequence BAEXPERIMENTALTreatment A (experimental): Two tablets of Combination tablet with paracetamol, guaifenesin and phenylephrine hydrochloride each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride Treatment B (active comparator): One sachet Vicks Active SymptoMax Plus, powder for oral solution, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride

Interventions

NameTypeDescription
Tablet paracetamol, guaifenesin and phenylephrine HCLDRUGEach subject will receive two tablets, each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride
Vicks Active SymptoMax Plus powder for oral solutionDRUGEach subject will receive one sachet, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 45 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Subjects being verified as "Healthy": "Healthy" is defined as absence of any diseases or abnormalities on the basis of physical examination, standard clinical laboratory, and instrumental examinations performed at the screening visit. 2. Females of childbearing potential must...

Countries:Russia
Unlock Eligibility Criteria